{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:45Z","timestamp":1787002665413,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41409-023-02086-1","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T07:02:36Z","timestamp":1692601356000},"page":"1223-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-5439","authenticated-orcid":false,"given":"Jiasheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Alkrekshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilatha","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-2751","authenticated-orcid":false,"given":"Hsin-Ti Cindy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elantably","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman Al","family":"Armashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-021-00741-9","volume":"18","author":"F Rosetti","year":"2022","unstructured":"Rosetti F, Madera-Salcedo IK, Rodriguez-Rodriguez N, Crispin JC. Regulation of activated T cell survival in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2022;18:232\u201344.","journal-title":"Nat Rev Rheumatol"},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.61.10.863","volume":"61","author":"RJ Looney","year":"2002","unstructured":"Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis. 2002;61:863\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1182\/bloodadvances.2020003176","volume":"4","author":"KS Jhaveri","year":"2020","unstructured":"Jhaveri KS, Schlam I, Holtzman NG, Peravali M, Richardson PK, Dahiya S, et al. Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy. Blood Adv. 2020;4:6019\u201322.","journal-title":"Blood Adv"},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/OARRR.S92630","volume":"7","author":"JG Hanly","year":"2015","unstructured":"Hanly JG, Thompson K, Skedgel C. The use of administrative health care databases to identify patients with rheumatoid arthritis. Open Access Rheumatol. 2015;7:69\u201375.","journal-title":"Open Access Rheumatol"},{"key":"2086_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2086_CR7","unstructured":"CMS. FY 2021 IPPS final rule. In: https:\/\/www.cms.gov\/medicare\/acute-inpatient-pps\/fy-2021-ipps-final-rule-home-page#1735, Accessed in 1\/2023."},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"E Baecklund","year":"1998","unstructured":"Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317:180\u20131.","journal-title":"BMJ"},{"key":"2086_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8:5.","journal-title":"Signal Transduct Target Ther"},{"key":"2086_CR10","doi-asserted-by":"publisher","first-page":"e126457","DOI":"10.1172\/jci.insight.126457","volume":"5","author":"IK Madera-Salcedo","year":"2019","unstructured":"Madera-Salcedo IK, S\u00e1nchez-Hern\u00e1ndez BE, Svyryd Y, Esquivel-Vel\u00e1zquez M, Rodr\u00edguez-Rodr\u00edguez N, Trejo-Zambrano MI, et al. PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. JCI Insight. 2019;5:e126457.","journal-title":"JCI Insight"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20:902\u201314.","journal-title":"Nat Immunol"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1615\/critrevimmunol.v25.i2.30","volume":"25","author":"G Nagy","year":"2005","unstructured":"Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol. 2005;25:123\u201340. https:\/\/doi.org\/10.1615\/critrevimmunol.v25.i2.30.","journal-title":"Crit Rev Immunol"},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372:eaba1786.","journal-title":"Science"},{"key":"2086_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","volume":"29","author":"S Kretschmann","year":"2023","unstructured":"Kretschmann S, V\u00f6lkl S, Reimann H, Kr\u00f6nke G, Schett G, Achenbach S, et al. Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus. Transpl Cell Ther. 2023;29:27\u201333.","journal-title":"Transpl Cell Ther"},{"key":"2086_CR16","doi-asserted-by":"publisher","first-page":"10380","DOI":"10.1182\/blood-2022-156120","volume":"140","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Chavez J, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. 3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/Refractory (R\/R) indolent Non-Hodgkin lymphoma (iNHL). Blood. 2022;140:10380\u20133.","journal-title":"Blood"},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02086-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T04:03:52Z","timestamp":1698897832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02086-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-02086-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}